stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Net margin
Mirum Pharmaceuticals, Inc.'s net margin over the twelve months to 30 September 2026 was −134.8%, down 130.3 percentage points from fiscal 2025 (−4.48%). Over the past ten years it has ranged from −438.9% (fiscal 2021) to 0.00% (fiscal 2020); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −4.48% | 21.62 |
| FY2024 | −26.1% | 61.58 |
| FY2023 | −87.7% | 88.37 |
| FY2022 | −176.1% | 262.80 |
| FY2021 | −438.9% | (438.85) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | −22.0% | 16.19 |
| Jun 2026 | −38.1% | 456.07 |
| Mar 2026 | −494.2% | (490.36) |
| Dec 2025 | −3.85% | (6.03) |
| 28 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 20.3% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| PTCT PTC Therapeutics, Inc. compare | −9.17% |
| IONS Ionis Pharmaceuticals, Inc. compare | −64.7% |
| MIRM Mirum Pharmaceuticals, Inc. | −134.8% |
| CGON CG Oncology, Inc. compare | −3,602.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement